In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on uniQure (QURE – Research Report), with a price ...

TD Cowen analyst Joseph Thome has maintained their bullish stance on QURE stock, giving a Buy rating today. Joseph Thome’s rating is ...

The only other gene therapies to have made it to market so far are uniQure’s Glybera’s (alipogene tiparvovec), and GSK’s Strimvelis, but both have only gained EU approval. Glybera is a case ...

So far only three commercial gene therapies have been approved across the globe. One of which, Glybera, was developed for the ultra-rare inherited disease familial lipoprotein lipase deficiency ...

Fundsmith Equity and other underperforming funds due for a resurgence ...